FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come
US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.
You may also be interested in...
US FDA's approval kept very limited amounts available the past two flu seasons; 2.7 million doses to be shipped for the 2018-2019 season.
US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.
CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.